Oncolys BioPharma, Inc.

Oncolys BioPharma Inc. researches, develops, manufactures, sells, and imports oncolytic viruses, drugs and medicines, and tumor diagnostic agents in Japan, the United States, and Asia. Its pipeline includes Telomelysin (OBP-301), an oncolytic viral immunotherapy in phase II trials for gastric cancer and phase I trials for HCC and esophageal cancer. The company also develops OBP-601 (Censavudine) in phase II trials for progressive supranuclear palsy, amyotrophic lateral sclerosis, and Aicardi-Goutières syndrome; OBP-702 in preclinical trials for pancreatic cancer and ophthalmology; OBP-201 in preclinical trials for viral infections; and TelomeScan (OBP-401 and OBP-1101) in pilot studies for cancer testing. Incorporated in 2004, it is headquartered in Minato, Japan.